Regenxbio Faces Legal Challenges Over RGX-111 and Concerns on RGX-202 Trial Results

Title: REGENXBIO Faces Legal Challenges Amid Concerns Over RGX-111 Gene Therapy

REGENXBIO Inc., a prominent player in the gene therapy sector, finds itself navigating turbulent waters as legal scrutiny intensifies regarding its gene therapy candidate RGX-111. The recent developments include a securities class action lawsuit targeting both the company and its Executive Vice President and Chief Medical Officer, Dr. Stephen Pakola. Central to these allegations are claims that REGENXBIO misrepresented essential information about the safety and efficacy of RGX-111, designed to treat severe Mucopolysaccharidosis Type I, commonly known as Hurler syndrome. This misconduct is underscored by assertions that the company concealed critical risks from investors, leading to substantial stock price fluctuations once those risks came to light.

The backdrop of these allegations is particularly stark. On January 28, 2026, the U.S. Food and Drug Administration (FDA) imposed a clinical hold on RGX-111 following a serious adverse event in a trial participant—specifically, the identification of an intraventricular central nervous system (CNS) tumor. This announcement triggered a dramatic stock decline of 17.8% in a single day, accentuating the urgency and gravity of the claims against REGENXBIO. The lawsuit alleges that, throughout the class period from February 2022 to January 2026, company representatives, including Dr. Pakola, downplayed the therapy's risks while highlighting its promising aspects, leading to investor misinformation about the drug's overall potential.

As legal proceedings continue, investors impacted by purported securities fraud are urged to explore their rights and consider becoming lead plaintiffs in the class action. This initiative is spearheaded by prominent law firms specializing in such cases, emphasizing no costs for participation. REGENXBIO's response to these developments and its ongoing commitment to transparency will be crucial in restoring investor confidence and navigating the complexities of the biotechnology landscape.

In addition to these legal challenges, REGENXBIO is concurrently addressing rising concerns regarding the interim results from its Phase 1/2 AFFINITY DUCHENNE trial for the gene therapy RGX-202, targeted at Duchenne muscular dystrophy (DMD). Although preliminary data emerged from this trial, it has fallen short of investor expectations, which may further complicate the company's market position.

As the situation unfolds, REGENXBIO remains at a crossroads, tasked with addressing both its legal challenges and the development of its gene therapies within a highly competitive sector. Industry stakeholders are closely monitoring potential regulatory impacts and the firm’s strategic responses in a quest for successful recovery and innovation in gene therapy solutions.